BriaCell's Phase 3 breast cancer study clears seventh DSMB review
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced that an independent Data Safety Monitoring Board (DSMB) has issued its ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
